Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

@article{Peggs2006PrinciplesAU,
  title={Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.},
  author={Karl S. Peggs and Sergio A. Quezada and Alan Jerry Korman and James P. Allison},
  journal={Current opinion in immunology},
  year={2006},
  volume={18 2},
  pages={
          206-13
        }
}

Figures and Tables from this paper

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity
TLDR
Reducing the systemic exposure of the host to the immune modulatory mAb correlated with reduced evidence of systemic autoimmunity and has broad utility for the delivery of mAbs or proteins locally from cellular immunotherapies to minimize IBEs while retaining the potent therapeutic effects of such combination treatments.
Update on anti-CTLA-4 antibodies in clinical trials
TLDR
Preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events are reviewed.
Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
TLDR
The immunogram - a newly described graphical synthesis of treatment data and immune correlates in individual patients - may help to confirm, reject or formulate new hypotheses regarding the mechanism of anti-CTLA-4 activity.
CTLA-4 blockade and the renaissance of cancer immunotherapy.
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
TLDR
Clinical and preclinical data indicate that CTLA-4 blockade results in direct activation of CD4+ and CD8+ effector cells, and anti-CTLA- 4 monoclonal antibody therapy has shown promise in a number of cancers, particularly melanoma.
Targeting Costimulatory Pathways for Tumor Immunotherapy
TLDR
As the authors gain a better understanding of the molecular and cellular consequences of T-cell signaling through the costimulatory pathways, a more rational approach to the activation or inhibition ofT-cell responses can be developed for the treatment of cancer and other immune-mediated diseases.
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
  • L. Fong, E. Small
  • Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Available clinical data suggest that anti-CTLA-4 mAbs are very different from traditional mAbs, chemotherapies, and immunotherapie in terms of patterns of response, duration ofresponse, and adverse event profile.
Antibody-based cancer therapy
  • C. Baxevanis
  • Biology, Medicine
    Expert opinion on drug discovery
  • 2008
TLDR
The results from preclinical and clinical studies demonstrate that mAbs can also promote tumor-specific active immunity, and the potential of combination immunotherapies using mAbs for the augmentation of adaptive antitumor immunity is summarized.
Tremelimumab: research and clinical development
TLDR
The use of tremelimumab as an immune checkpoint therapeutic agent is a promising approach alone or in combination with other anticancer drugs, and a number of clinical trials against solid tumors are reviewed.
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.
TLDR
It is demonstrated that anti-CTLA-4 mAb therapy induces motility of TIL and that NKG2D ligation offsets this effect to enhance TILs arrest and antitumor activity.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 64 REFERENCES
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
TLDR
This review will focus on the T-cell co-stimulatory molecule CTLA4, which has entered clinical trials and demonstrated objective clinical responses, initially for metastatic melanoma and has been associated with organ-specific inflammatory adverse events.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
  • F. Hodi, M. Mihm, G. Dranoff
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
TLDR
Findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
  • G. Phan, J. Yang, S. Rosenberg
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
TLDR
This study establishes CTLA-4 as an important molecule regulating tolerance to “self” antigens in humans and suggests a role for CTla-4 blockade in breaking tolerance to human cancer antIGens for cancer immunotherapy.
Enhancement of Antitumor Immunity by CTLA-4 Blockade
TLDR
In vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors, and this rejection resulted in immunity to a secondary exposure to tumor cells, suggesting that blockade of the inhibitory effects of CTLA4 can allow for, and potentiate, effective immune responses against tumor cells.
CTLA-4: new insights into its biological function and use in tumor immunotherapy
TLDR
Recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses are summarized and preclinical and clinical results that indicate manipulation of CTla-4 has considerable promise as a strategy for the immunotherapy of cancer are described.
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
TLDR
Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti- CTLA-4 mAb therapy developed uveitis, the first report of autoimmune disease involving the eye in patients treated with anti-CTLA- 4 mAb.
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
TLDR
It is demonstrated that an effective immune response against primary prostate tumors in transgenic (TRAMP) mice can be elicited using a strategy that combines CTLA-4 blockade and an irradiated tumor cell vaccine, and suggest potential of this approach for treatment of prostate cancer.
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
TLDR
It is established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis.
Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques
TLDR
Observations support the development of CTLA-4 blockade for human immunotherapy and banishes the possibility of monkey anti-human Ab responses in the monkeys.
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.
TLDR
It is found that while CTLA-4 blockade enhanced the priming of responsive T cells, it did not prevent the induction of tolerance to tumor antigens, and this results demonstrate that there is a critical window in which the combination of CTLA -4 blockade and vaccination achieves an optimal response.
...
1
2
3
4
5
...